I agree Kenny73. Cash outflow is from $743k up to to $1.38M this qtr so it looks like activity is going to ramp (86% increase).
The guys at Sprout8 have also released a second infographic on RHY which looks into the following:
-ColoSTAT compared to the competition (They've put together a really cool quadrant).
- Fairly detailed analysis on the efficacy of ColoSTAT compared to the competition.
- Costing
- Why ColoSTAT is the most likely to be adopted as the preferred test in the screening space for colorectal cancer.
Worth checking out below.
http://sprout8.com/infographic-excellent-prognosis-developments-in-colorectal-cancer-testing-what-is-likely-to-become-the-preferred-test-for-population-screening-part-2-of-2/
Cheers,
